Astria Therapeutics

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 563.92
5.66 1.01
86,090
392.20M
US$ 221.170B
US$ 249.54
1.37 0.55
207,690
728.30M
US$ 181.740B
US$ 98.43
0.38 0.39
608,593
1.74B
US$ 171.270B
US$ 80.43
1.05 1.32
973,316
1.33B
US$ 106.970B
US$ 279.64
2.95 1.07
83,758
378.43M
US$ 105.820B
US$ 255.11
-1.31 -0.51
347,534
353.38M
US$ 90.150B
US$ 48.33
0.11 0.23
886,937
1.43B
US$ 69.100B
US$ 242.26
1.76 0.73
82,175
284.27M
US$ 68.870B
US$ 81.46
0.70 0.87
1.09M
618.26M
US$ 50.360B
US$ 348.91
2.35 0.68
104,989
141.79M
US$ 49.470B
US$ 117.64
3.55 3.11
235,850
386.26M
US$ 45.440B
US$ 489.71
4.19 0.86
28,084
82.90M
US$ 40.600B
US$ 133.36
1.39 1.05
261,043
295.70M
US$ 39.430B
US$ 190.17
1.82 0.97
69,947
185.74M
US$ 35.320B
US$ 220.24
0.24 0.11
66,775
157.30M
US$ 34.640B
US$ 68.12
0.63 0.93
112,664
490.09M
US$ 33.380B
US$ 1.00
20.91 1.43
6,248
22.29M
US$ 33.000B
US$ 157.10
0.69 0.44
124,199
202.26M
US$ 31.770B
US$ 216.00
3.42 1.61
40,643
146.91M
US$ 31.730B
US$ 126.91
0.87 0.69
67,200
209.85M
US$ 26.630B
US$ 337.41
3.11 0.93
18,702
74.03M
US$ 24.980B
US$ 308.34
1.64 0.53
59,451
78.11M
US$ 24.080B
US$ 311.68
1.51 0.49
177,232
69.45M
US$ 21.650B
US$ 39.64
0.41 1.05
681,866
504.12M
US$ 19.980B
US$ 79.72
0.52 0.66
56,891
246.55M
US$ 19.650B
US$ 219.99
1.58 0.72
67,853
88.60M
US$ 19.490B
US$ 186.93
1.73 0.93
35,139
99.82M
US$ 18.660B
US$ 70.90
0.53 0.75
1.06M
262.13M
US$ 18.590B
US$ 303.26
3.30 1.10
30,375
59.41M
US$ 18.020B
US$ 358.55
3.53 0.99
43,341
49.43M
US$ 17.720B
US$ 208.55
1.81 0.88
218,117
81.72M
US$ 17.040B
US$ 128.45
0.87 0.68
46,654
126.32M
US$ 16.230B
US$ 139.71
-0.35 -0.25
130,653
113.89M
US$ 15.910B
US$ 28.05
0.25 0.90
128,649
436.68M
US$ 12.250B
US$ 66.51
0.23 0.35
194,721
179.23M
US$ 11.920B
US$ 249.95
1.02 0.41
11,629
46.91M
US$ 11.730B
US$ 465.30
4.52 0.98
7,025
24.75M
US$ 11.520B
US$ 75.55
-0.22 -0.29
34,857
147.08M
US$ 11.110B
US$ 277.22
2.55 0.93
12,486
37.98M
US$ 10.530B
US$ 46.22
0.07 0.15
41,390
227.70M
US$ 10.520B
US$ 79.97
0.80 1.01
70,632
131.28M
US$ 10.500B
US$ 195.92
2.13 1.10
34,719
50.88M
US$ 9.970B
US$ 165.16
4.91 3.06
48,386
55.52M
US$ 9.170B
US$ 174.28
1.40 0.81
8,617
52.56M
US$ 9.160B
US$ 37.30
0.05 0.13
108,767
214.91M
US$ 8.020B
US$ 217.96
3.72 1.74
28,656
36.14M
US$ 7.880B
US$ 250.38
2.03 0.82
28,957
28.89M
US$ 7.230B
US$ 38.42
0.17 0.44
62,020
163.04M
US$ 6.260B
US$ 23.29
-0.02 -0.09
8,557
264.70M
US$ 6.160B
US$ 56.44
-0.21 -0.37
96,754
109.03M
US$ 6.150B
US$ 57.10
-0.08 -0.14
37,195
104.95M
US$ 5.990B
US$ 86.81
-0.27 -0.31
16,578
66.05M
US$ 5.730B
US$ 183.86
1.92 1.06
14,296
31.10M
US$ 5.720B
US$ 16.32
0.41 2.58
259,968
350.00M
US$ 5.710B
US$ 81.70
0.27 0.33
175,138
68.83M
US$ 5.620B
US$ 17.49
0.17 0.98
60,213
282.11M
US$ 4.930B
US$ 55.16
0.21 0.38
16,016
81.64M
US$ 4.500B
US$ 53.77
0.63 1.19
75,619
77.41M
US$ 4.160B
US$ 72.41
0.33 0.46
6,249
56.92M
US$ 4.120B
US$ 18.35
0.13 0.71
114,540
216.15M
US$ 3.970B
US$ 78.32
0.89 1.15
5,747
50.61M
US$ 3.960B
US$ 157.14
0.91 0.58
10,390
24.00M
US$ 3.770B
US$ 122.65
1.44 1.19
20,032
30.11M
US$ 3.690B
US$ 35.03
0.51 1.48
119,897
102.90M
US$ 3.600B
US$ 62.24
0.24 0.39
50,208
54.31M
US$ 3.380B
US$ 62.43
0.15 0.24
9,312
49.53M
US$ 3.090B
US$ 100.63
3.63 3.74
105,862
30.48M
US$ 3.070B
US$ 63.76
0.14 0.22
33,281
48.21M
US$ 3.070B
US$ 42.57
0.47 1.12
47,458
69.05M
US$ 2.940B
US$ 56.61
0.57 1.02
48,385
49.53M
US$ 2.800B
US$ 22.78
-0.02 -0.09
3,195
119.10M
US$ 2.710B
US$ 41.58
-0.53 -1.26
69,288
64.30M
US$ 2.670B
US$ 26.65
0.09 0.34
41,673
97.07M
US$ 2.590B
US$ 77.10
0.42 0.55
14,232
33.13M
US$ 2.550B
US$ 30.48
0.45 1.50
78,412
83.08M
US$ 2.530B
US$ 24.42
0.24 0.99
270,567
102.66M
US$ 2.510B
US$ 75.58
0.87 1.16
31,450
31.92M
US$ 2.410B
US$ 50.16
0.81 1.64
9,764
47.70M
US$ 2.390B
US$ 9.45
-0.16 -1.66
433,784
246.23M
US$ 2.330B
US$ 42.06
0.35 0.84
25,792
53.52M
US$ 2.250B
US$ 17.71
0.84 4.98
218,851
126.30M
US$ 2.240B
US$ 37.90
0.82 2.21
156,266
52.13M
US$ 1.980B
US$ 14.21
0.38 2.75
58,199
134.73M
US$ 1.910B
US$ 40.91
0.08 0.20
19,589
46.51M
US$ 1.900B
US$ 23.43
-0.29 -1.22
68,296
81.03M
US$ 1.900B
US$ 71.33
0.38 0.54
3,000
24.34M
US$ 1.740B
US$ 15.97
0.14 0.88
261,102
105.06M
US$ 1.680B
US$ 38.85
0.76 2.00
23,015
38.12M
US$ 1.480B
US$ 24.87
0.12 0.48
36,049
55.50M
US$ 1.380B
US$ 23.66
0.31 1.33
16,223
57.36M
US$ 1.360B
US$ 16.72
0.05 0.30
17,476
81.52M
US$ 1.360B
US$ 29.05
0.48 1.68
9,553
46.50M
US$ 1.350B
US$ 27.44
0.23 0.85
67,011
47.66M
US$ 1.310B
US$ 29.05
-0.64 -2.16
33,115
44.72M
US$ 1.300B
US$ 33.19
0.73 2.25
60,039
35.43M
US$ 1.180B
US$ 8.58
0.14 1.66
28,607
134.85M
US$ 1.160B
US$ 640.31
0.00 0.00
0
1.77M
US$ 1.130B
US$ 51.17
0.34 0.67
1,601
22.00M
US$ 1.130B
US$ 45.10
0.06 0.13
8,629
24.69M
US$ 1.110B
US$ 93.48
1.04 1.13
7,774
10.88M
US$ 1.020B
US$ 1.30
0.0015 0.12
179,005
772.69M
US$ 1.010B
US$ 12.67
0.30 2.43
66,058
76.23M
US$ 965.450M
US$ 42.00
0.12 0.29
9,306
22.89M
US$ 961.380M
US$ 9.91
-0.06 -0.60
163,121
95.95M
US$ 950.860M
US$ 19.33
0.21 1.10
32,526
48.31M
US$ 933.590M
US$ 21.82
0.29 1.35
60,429
42.77M
US$ 933.030M
US$ 16.45
0.27 1.67
145,074
56.65M
US$ 931.890M
US$ 31.09
-0.03 -0.10
31,750
29.52M
US$ 917.850M
US$ 19.85
0.01 0.05
25,893
41.88M
US$ 831.320M
US$ 18.04
0.10 0.56
9,418
40.10M
US$ 723.400M
US$ 19.86
0.27 1.38
4,541
34.50M
US$ 685.170M
US$ 2.25
0.02 0.67
170,530
286.74M
US$ 643.730M
US$ 3.37
0.01 0.30
100,690
181.42M
US$ 611.390M
US$ 22.71
0.20 0.89
18,133
26.35M
US$ 598.410M
US$ 15.84
0.22 1.41
6,554
35.73M
US$ 565.960M
US$ 26.80
-0.27 -1.00
25,544
19.62M
US$ 525.820M
US$ 12.07
0.14 1.17
5,884
40.33M
US$ 486.780M
US$ 9.08
0.13 1.45
55,189
53.54M
US$ 486.140M
US$ 12.37
0.32 2.66
16,998
39.13M
US$ 484.040M
US$ 37.89
-0.15 -0.39
3,226
12.57M
US$ 476.280M
US$ 9.92
0.01 0.10
51,440
47.55M
US$ 471.700M
US$ 16.97
0.30 1.80
23,165
27.72M
US$ 470.410M
US$ 9.05
0.17 1.91
3,676
48.15M
US$ 435.760M
US$ 11.37
0.29 2.62
23,513
37.41M
US$ 425.350M
US$ 10.97
-0.02 -0.18
9,874
38.50M
US$ 422.340M
US$ 5.81
0.02 0.35
39,510
72.62M
US$ 421.560M
US$ 4.05
-0.04 -0.98
20,499
102.05M
US$ 413.300M
US$ 11.22
-0.02 -0.18
2,133
36.15M
US$ 405.500M
US$ 10.74
0.15 1.42
11,150
37.05M
US$ 397.730M
US$ 10.24
0.04 0.39
9,018
38.02M
US$ 389.320M
US$ 9.17
0.11 1.21
17,485
42.29M
US$ 387.800M
US$ 3.40
0.01 0.29
25,525
113.67M
US$ 386.480M
US$ 5.31
-0.03 -0.56
45,820
71.17M
US$ 377.910M
US$ 13.53
0.69 5.37
31,824
25.03M
US$ 338.660M
US$ 16.78
0.22 1.33
31,559
20.15M
US$ 338.120M
US$ 0.70
-0.01 -1.87
447,318
478.26M
US$ 335.740M
US$ 91.86
0.00 0.00
0
3.63M
US$ 333.450M
US$ 1.90
-0.06 -3.01
209,502
174.14M
US$ 331.040M
US$ 38.94
0.56 1.46
856
8.30M
US$ 323.200M
US$ 1.28
-0.01 -0.78
1.09M
242.90M
US$ 310.910M
US$ 5.79
0.08 1.40
138,837
52.27M
US$ 302.380M
US$ 2.85
-0.05 -1.72
2,417
105.72M
US$ 301.300M
US$ 7.89
0.01 0.13
14,711
37.96M
US$ 299.500M
US$ 12.45
0.04 0.32
13,517
22.92M
US$ 285.240M
US$ 2.83
0.02 0.53
8,227
93.78M
US$ 264.930M
US$ 18.71
0.30 1.63
4,040
14.13M
US$ 264.370M
US$ 8.06
0.17 2.15
37,581
31.71M
US$ 255.580M
US$ 6.51
0.14 2.20
43,289
35.61M
US$ 231.820M
CA$ 1.54
0.00 0.00
0
144.83M
CA$ 223.040M
US$ 2.07
0.17 8.68
193,328
102.72M
US$ 212.120M
US$ 1.61
0.005 0.31
71,261
119.88M
US$ 192.410M
US$ 7.96
-0.11 -1.36
4,347
23.94M
US$ 190.560M
US$ 6.33
0.19 3.09
56,451
30.03M
US$ 190.090M
US$ 7.35
0.34 4.85
15,265
25.85M
US$ 190.000M
US$ 9.88
-0.17 -1.69
1,457
19.16M
US$ 189.270M
US$ 2.48
0.04 1.67
91,423
75.59M
US$ 187.520M
US$ 8.98
-0.19 -2.07
6,120
20.88M
US$ 187.500M
US$ 8.97
0.14 1.59
8,765
20.63M
US$ 184.950M
US$ 25.80
0.07 0.27
9,052
6.84M
US$ 176.470M
US$ 0.63
-0.008 -1.25
22,442
278.66M
US$ 176.110M
US$ 3.87
-0.15 -3.73
5,794
45.28M
US$ 175.230M
US$ 7.97
0.02 0.25
5,446
20.66M
US$ 164.660M
US$ 6.30
0.10 1.61
28,012
26.09M
US$ 164.370M
US$ 2.05
-0.02 -0.97
58,205
79.30M
US$ 162.560M
US$ 1.49
-0.0085 -0.57
402
99.53M
US$ 148.300M
US$ 0.62
-0.03 -4.42
109,320
236.84M
US$ 147.150M
US$ 3.30
-0.10 -2.94
14,185
43.64M
US$ 144.010M
US$ 1.88
0.03 1.54
6,156
74.84M
US$ 140.590M
US$ 3.12
0.02 0.60
58,234
42.19M
US$ 131.570M
US$ 1.71
-0.02 -1.16
690
76.50M
US$ 130.820M
US$ 3.75
0.00 0.00
0
32.79M
US$ 122.800M
US$ 4.71
-0.01 -0.21
31,524
25.62M
US$ 120.670M
US$ 3.79
0.03 0.80
16,973
29.61M
US$ 112.220M
US$ 0.68
0.07 10.66
96,060
165.05M
US$ 111.410M
US$ 2.20
0.03 1.50
53,364
48.72M
US$ 107.310M
US$ 2.87
0.05 1.77
201
37.23M
US$ 106.850M
US$ 4.16
0.09 2.21
58,634
25.68M
US$ 106.830M
US$ 2.97
0.05 1.54
2,501
34.60M
US$ 102.590M
US$ 15.67
0.00 0.00
0
6.54M
US$ 102.460M
CA$ 1.56
-0.08 -4.88
17,616
64.34M
CA$ 100.370M
US$ 4.02
0.00 0.00
0
24.90M
US$ 100.000M
US$ 1.94
0.12 6.59
22,316
49.76M
US$ 96.530M
US$ 6.64
0.31 4.90
92,263
14.49M
US$ 96.260M
US$ 3.12
-0.18 -5.45
86,733
30.21M
US$ 94.260M
US$ 1.04
0.08 8.33
431
90.60M
US$ 94.220M
US$ 1.62
-0.03 -1.82
4,990
57.52M
US$ 93.180M
US$ 10.54
0.11 1.05
622
8.49M
US$ 89.460M
US$ 4.24
-0.04 -0.93
10,835
20.73M
US$ 87.900M
CA$ 0.32
0.00 0.00
0
278.22M
CA$ 87.640M
US$ 5.35
0.00 0.00
0
16.05M
US$ 85.870M
US$ 5.09
0.06 1.19
23,012
16.61M
US$ 84.540M
US$ 1.34
0.03 2.29
12,773
61.95M
US$ 83.010M
US$ 29.49
-0.39 -1.31
1,406
2.75M
US$ 81.100M
US$ 1.13
0.03 2.73
47,305
71.40M
US$ 80.680M
US$ 2.95
0.14 4.98
23,562
27.22M
US$ 80.300M
US$ 0.68
-0.006 -0.87
4,399
108.66M
US$ 74.320M
US$ 1.29
0.02 1.57
12,455
55.62M
US$ 71.750M
0.75
0.00 0.00
15,500
94.34M
70.760M
US$ 2.15
0.01 0.47
280
30.60M
US$ 65.790M
US$ 1.11
-0.0086 -0.77
281,274
58.62M
US$ 65.150M
US$ 0.90
0.00 0.00
0
69.80M
US$ 62.820M
CA$ 0.28
0.00 0.00
0
216.50M
CA$ 60.620M
US$ 5.92
1.08 22.31
181,185
10.05M
US$ 59.500M
US$ 16.50
0.00 0.00
0
3.58M
US$ 59.070M
CA$ 0.61
0.00 0.00
4,400
94.22M
CA$ 57.470M
US$ 1.73
-0.05 -2.81
1,069
32.94M
US$ 56.990M
US$ 1.38
-0.02 -1.43
494
39.11M
US$ 53.970M
US$ 0.99
0.0005 0.05
2,600
50.74M
US$ 49.980M
US$ 1.09
-0.02 -1.68
10,305
45.62M
US$ 49.790M
US$ 0.39
-0.02 -5.11
89,344
124.60M
US$ 48.590M
US$ 0.48
-0.0065 -1.33
23,521
99.10M
US$ 47.610M
US$ 2.89
0.04 1.40
5,667
16.29M
US$ 47.080M
US$ 4.78
-0.02 -0.42
621
9.47M
US$ 45.220M
US$ 1.22
-0.03 -2.40
241
36.44M
US$ 44.460M
US$ 1.37
-0.02 -1.76
33,996
30.92M
US$ 42.220M
US$ 0.67
-0.004 -0.59
23,760
62.02M
US$ 41.620M
CA$ 0.36
0.00 0.00
0
112.15M
CA$ 40.370M
US$ 0.34
0.0058 1.71
15,841
114.85M
US$ 39.570M
US$ 2.18
-0.05 -2.24
2,250
16.32M
US$ 35.580M
US$ 0.91
-0.03 -2.67
14,390
38.11M
US$ 34.680M
US$ 1.00
0.01 1.29
1,025
34.72M
US$ 34.580M
US$ 2.10
0.00 0.00
0
15.99M
US$ 33.580M
US$ 0.35
-0.005 -1.40
41,033
93.70M
US$ 32.910M
CA$ 0.21
-0.005 -2.33
16,500
156.51M
CA$ 32.870M
CA$ 0.22
0.005 2.33
7,500
146.56M
CA$ 32.240M
US$ 2.98
0.01 0.34
4,949
10.73M
US$ 31.980M
US$ 1.88
0.01 0.70
7,346
16.54M
US$ 31.140M
CA$ 0.31
0.005 1.64
21,325
98.62M
CA$ 30.570M
CA$ 0.58
-0.03 -4.92
14,380
52.47M
CA$ 30.430M
US$ 1.56
0.00 0.00
322
18.98M
US$ 29.610M
US$ 5.17
0.01 0.19
1,158
5.64M
US$ 29.160M
US$ 0.72
0.00 0.00
0
40.33M
US$ 29.040M
US$ 1.63
-0.01 -0.61
8,396
16.24M
US$ 26.470M
US$ 1.96
0.00 0.00
0
13.48M
US$ 26.420M
US$ 2.24
0.00 0.00
0
11.02M
US$ 24.680M
US$ 0.68
0.00 0.00
0
35.02M
US$ 23.960M
US$ 0.46
0.0016 0.35
3,399
50.68M
US$ 23.390M
US$ 0.30
-0.0053 -1.76
38,753
78.75M
US$ 23.240M
US$ 0.79
0.01 1.66
30,439
28.45M
US$ 22.590M
US$ 1.74
0.06 3.57
1,004
12.76M
US$ 22.200M
US$ 1.13
0.03 2.77
134,911
19.24M
US$ 21.750M
US$ 1.93
0.04 2.12
247
11.24M
US$ 21.690M
US$ 0.07
0.0006 0.93
60,866
320.29M
US$ 20.850M
0.40
-0.02 -3.61
10,500
51.86M
20.740M
CA$ 0.31
0.02 6.90
21,000
66.73M
CA$ 20.690M
US$ 1.55
0.03 1.97
4,881
13.14M
US$ 20.370M
US$ 0.74
-0.04 -4.63
3,285
27.08M
US$ 20.140M
US$ 2.49
-0.03 -1.15
765
8.00M
US$ 19.890M
CA$ 0.36
0.005 1.43
1,000
53.81M
CA$ 19.100M
US$ 0.46
0.00 0.00
0
40.60M
US$ 18.680M
US$ 2.12
0.09 4.43
3,733
8.71M
US$ 18.470M
US$ 0.76
0.0001 0.01
754
24.10M
US$ 18.320M
CA$ 0.05
0.005 12.50
57,875
406.25M
CA$ 18.280M
US$ 1.54
0.07 4.76
150,520
11.81M
US$ 18.190M
US$ 2.27
0.00 0.00
0
7.89M
US$ 17.910M
0.22
0.00 0.00
0
83.29M
17.910M
US$ 1.60
-0.05 -3.02
134
10.93M
US$ 17.490M
CA$ 0.07
0.005 7.69
11,500
239.53M
CA$ 16.770M
CA$ 0.28
-0.005 -1.79
12,000
59.82M
CA$ 16.450M
US$ 0.14
0.00 0.00
0
111.89M
US$ 16.090M
US$ 0.60
-0.01 -1.72
7,596
26.71M
US$ 16.030M
US$ 1.41
0.09 6.44
479
11.08M
US$ 15.570M
US$ 0.68
0.03 4.51
4,712
22.82M
US$ 15.500M
US$ 1.53
0.07 4.79
5,696
10.10M
US$ 15.450M
US$ 1.78
-0.05 -2.57
921
8.37M
US$ 14.920M
CA$ 0.11
0.00 0.00
0
140.64M
CA$ 14.770M
US$ 1.13
0.07 6.28
18,786
12.91M
US$ 14.540M
US$ 0.39
-0.001 -0.26
70,385
36.71M
US$ 14.280M
US$ 1.14
-0.09 -7.32
5,858
11.81M
US$ 13.460M
US$ 0.50
0.01 2.52
4,413
26.78M
US$ 13.390M
US$ 1.29
0.04 3.20
864
9.41M
US$ 12.140M
US$ 0.17
-0.02 -11.08
374,615
69.33M
US$ 11.580M
US$ 1.49
0.04 2.76
3,473
7.76M
US$ 11.560M
US$ 1.29
-0.02 -1.53
362
8.92M
US$ 11.510M
CA$ 0.06
0.00 0.00
71,000
183.80M
CA$ 11.030M
US$ 0.02
0.00 0.00
0
467.20M
US$ 10.980M
CA$ 0.11
0.005 5.00
4,715
101.53M
CA$ 10.660M
US$ 0.10
0.00 0.00
0
105.40M
US$ 10.540M
US$ 1.02
0.00 0.00
0
10.32M
US$ 10.530M
US$ 1.06
0.08 8.16
9,453
9.67M
US$ 10.250M
US$ 3.09
0.14 4.75
1,666
3.16M
US$ 9.760M
US$ 1.69
-0.03 -1.46
680
5.57M
US$ 9.390M
US$ 0.38
0.01 3.68
9,587
24.17M
US$ 9.180M
US$ 1.09
-0.005 -0.46
4,897
8.34M
US$ 9.050M
US$ 1.18
-0.02 -1.67
3,076
7.52M
US$ 8.870M
US$ 0.44
0.01 2.33
2,876
20.15M
US$ 8.870M
US$ 0.37
-0.0089 -2.34
4,337
22.95M
US$ 8.520M
US$ 0.34
-0.0088 -2.56
28,465
25.01M
US$ 8.390M
US$ 0.08
-0.02 -19.64
12,150
96.89M
US$ 7.770M
US$ 1.33
0.0064 0.48
4,537
5.80M
US$ 7.690M
US$ 0.63
0.03 4.47
7,221
12.17M
US$ 7.630M
US$ 1.03
0.00 0.00
0
7.28M
US$ 7.500M
US$ 4.26
0.11 2.65
5,124
1.64M
US$ 6.990M
US$ 0.24
-0.01 -4.90
9,960
28.21M
US$ 6.840M
US$ 0.81
-0.01 -1.38
13,001
7.44M
US$ 6.000M
CA$ 0.06
0.00 0.00
0
87.16M
CA$ 5.230M
US$ 0.43
0.02 5.24
10,801
11.89M
US$ 5.110M
US$ 0.30
0.003 1.03
21,016
17.06M
US$ 5.030M
US$ 0.41
0.00 0.00
0
11.76M
US$ 4.760M
US$ 1.46
-0.04 -2.35
77,500
3.22M
US$ 4.690M
US$ 0.62
0.02 3.07
42,496
7.05M
US$ 4.350M
US$ 2.00
0.02 1.01
128,926
1.96M
US$ 3.920M
US$ 3.70
-0.15 -3.90
29,235
1.04M
US$ 3.850M
US$ 0.25
0.009 3.75
1,379
15.30M
US$ 3.810M
US$ 0.81
-0.03 -3.17
709
4.66M
US$ 3.790M
US$ 0.49
-0.02 -3.00
149,819
7.32M
US$ 3.550M
US$ 3.31
-0.04 -1.19
11,929
1.02M
US$ 3.380M
US$ 1.48
0.04 2.77
1,941
2.16M
US$ 3.200M
US$ 4.90
0.04 0.82
2,525
536,394
US$ 2.630M
US$ 0.03
0.00 0.00
0
72.90M
US$ 2.270M
0.02
0.00 0.00
0
118.77M
1.780M
US$ 0.17
-0.0019 -1.08
4,261
9.68M
US$ 1.690M
US$ 2.87
-0.21 -6.82
29,181
483,528
US$ 1.390M
US$ 0.006
0.00 0.00
69,000
172.88M
US$ 1.040M
US$ 0.15
0.00 0.00
0
6.56M
US$ 984K
US$ 0.06
0.00 0.00
0
10.72M
US$ 611K
US$ 0.80
0.00 0.00
0
25,854
US$ 21K
US$ 0.0036
0.00 0.00
0
4.01M
US$ 14K
US$ 0.75
0.00 0.00
0
-
US$ -
US$ 0.77
0.03 4.05
19,173
-
US$ -
US$ 1.30
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease

As demand for clinical next-generation sequencing grows, Illumina Connected Insights enables user to streamline data interpretation and report generation to inform precision care SAN DIEGO, March 27, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of Connected Insights, a new cloud-based software enabling tertiary analysis for clinical next-generation sequencing (NGS) d... Read more


Syneos Health Launches Medical Affairs Digital Amplifier

MORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital Amplifier, a program designed to drive smarter and more effective scientific exchange. This integrated program seeks to ensure customers, and the clinicians they serve, have access to the latest education to optimize patient outcomes. The development of this unique... Read more


Delcath Systems Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023

NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the US Food and Drug Administration (FDA) has accepted Delcath Systems, Inc.'s (Delcath) new drug application resubmission for HEPZATO™ Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) seeking approval for the treatment of patients with unresectable... Read more


DarioHealth Selected as Digital Therapeutics Partner by a Top-Ten Digitally Enabled Pharmacy Benefits Manager

New agreement is the first contract resulting from strategic partnership with Sanofi NEW YORK, March 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced a new contract with a leading nationwide Pharmacy Benefits Manager (the "PBM") operating in 50 states to provide Dario's digital therapeutics, starting with the diabetes solution, to employer clients beginning in the... Read more


G Medical Innovations And Micare Path Announce Joint Collaboration To Provide Innovative Remote Patient Monitoring Solutions Globally

Rehovot, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”), a global leader in next-generation mobile health (mHealth) and digital health, and MiCare Path, a leader in optimized patient care through remote patient monitoring, today announced a collaboration to incorporate MiCare Path’s solutions and G Medical Innovations’ solutions. As part of the collaboration, G Medical... Read more


Genetic Technologies: GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation

MELBOURNE, Australia, March 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the US launch of three (3) new diseases taking the total number of individual risk assessments included in the geneType Multi-Test to nine (9), all from the one simple saliva sample. This launch is in line with phase 2 rollout... Read more


Petvivo Holdings To Exhibit At The IVAPM Pain Management Forum In Atlanta, Georgia 

MINNEAPOLIS, March 27, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it is a Platinum Sponsor and will be exhibiting at the International Veterinary Academy of Pain Management (“IVAPM”) Pain Management Forum to be held April 2nd to April 4th 2023 at the Westin Peachtree Plaza in Atlanta, Georgia. PetVivo... Read more


Delcath Systems Announces up to $85 Million Financing

Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with up to an additional $60 million tied to satisfaction of milestones Aggregate financing expected to be sufficient to fund Company through potential approval of HEPZATO and commercialization NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems,... Read more


BioSig Technologies Announces New Advisory Board Member Edwin Wang

Westport, CT, March 27, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of new Advisory Board member Edwin Wang. Mr. Wang has over 20 years of impactful experience in private equity, venture capital, merchant... Read more


Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

NEW YORK, March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022. Recent Business Highlights During and since the fourth quarter, Delcath Systems, Inc. (Delcath or the Company): Received an acceptance of the NDA resubmission from... Read more


Medigus: Viewbix Reports its Financial Results for 2022 with a 114% Growth in Revenues Totaling $97 Million

Viewbix is a subsidiary of Gix Internet whose results are consolidated with Medigus’ financial statements Tel Aviv, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that Viewbix Inc. (henceforth “Viewbix”) (OTC: VBIX), 76% owned by Medigus’ subsidiary Gix Internet, (henceforth “Gix”)... Read more


Venus Concept Announces Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Revenue Guidance

TORONTO, March 27, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2022. Fourth Quarter 2022 Summary & Recent Highlights: Total revenue of $24.3 million, down $8.3 million, or 26%, year-over-year; up $2.7 million, or 13% quarter-over-quarter. U.S. revenue down 14% year-over-year; up... Read more


Nexalin Technology Provides 2022 Year-End Business Update

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided a business update for the year ended December 31, 2022. Mark White, CEO of Nexalin Technology stated, “Nexalin has made significant progress towards commencing clinical trials of our Gen-2 and Gen-3 neurostimulation devices in the United States. Nexalin’s enhanced neurostimulation devices combine innovation, frequencies and algorithms... Read more


Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases

SAN DIEGO / Mar 24, 2023 / Business Wire / Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123). This first patient was seen at the UT Southwestern Medical Center, one of the largest and most respected hospitals in the nation. The FORESEE trial is a multicenter, prospective... Read more


BioSig Technologies Announces New Advisory Board Member Lorraine Spurge

Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of Lorraine Spurge, entrepreneur and financier, to its Advisory Board. As founder and CEO of Maple Stone Capital Advisors, Ms. Spurge... Read more


Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization Management to host Investor Day on April 6, 2023 TORONTO, March 24, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year... Read more


electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

ROCKAWAY, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a paper entitled “Non-Invasive Vagus Nerve Stimulation Improves Brain Lesion Volume and Neurobehavioral Outcomes in a Rat Model of Traumatic Brain Injury” in the peer-reviewed Journal of Neurotrauma. The lead author is Dr. Afshin Divani of the University of New Mexico, who... Read more


New evidence demonstrates Smith+Nephew's COBLATION™ Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques

LONDON, March 23, 2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces results from new scientific research that shows its COBLATION Intracapsular Tonsillectomy (CIT) technique can lead to improved post-operative outcomes in patients versus total tonsillectomy techniques. The research was recently published online by OTO Open: The Open Access Journal of the American Academy of Otolaryngology-Head and Neck Surgery... Read more


Establishment Labs Announces First Mia Femtech™ Partners in Europe and Second Partner Chain in Japan

NEW YORK / Mar 23, 2023 / Business Wire / Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into agreements with four partners in Europe and a second partner chain in Japan for Mia Femtech™ (“Mia®”). “Our global rollout of Mia Femtech continues, and we are pleased to announce our first European... Read more


TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

MALVERN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's OviTex PRS Long-Term Resorbable product. OviTex PRS Long-Term Resorbable is intended... Read more


ZimVie’s Exclusive Puros® Cancellous Particulate Allograft Dental Bone Grafting Solution Excels in Landmark Comparative Study in The International Journal of Oral & Maxillofacial Implants

WESTMINSTER, Colo., March 23, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced the publication of an article titled Comparison of the Effects of Tissue Processing on the Physicochemical Properties of Bone Allografts in The International Journal of Oral & Maxillofacial Implants. ZimVie Dental’s Puros Cancellous Particulate Allograft bone substitute was shown to have a microstructure... Read more


Therma Bright Prepares Launch of Digital Cough Screening and Data Collection Smartphone Application

Toronto, Ontario--(Newsfile Corp. - March 23, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company and AI4LYF are preparing to launch DCT, its digital cough data collection and screening smartphone application. On February 16, 2023, Therma Bright announced that it acquired the exclusive worldwide... Read more


T2 Biosystems Affirms Plans to Add Candida Auris Detection to the FDA-Cleared T2Candida Panel

LEXINGTON, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today affirmed plans to add detection of the fungal pathogen Candida auris to the Company’s FDA-cleared and CE marked T2Candida® Panel. According to a March 21, 2023 Wall Street Journal report, Candida auris is a multidrug-resistant pathogen labeled by the Centers for Disease Control... Read more


Avricore Health’s HealthTab™ Passes 530 Locations, Adds Virus Detection

VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) continues to grow the HealthTab™ network of pharmacy locations, reaching 532 locations. In 100 of these locations, the Company will be deploying Abbott’s ID Now™, either in combination with the Afinion 2™ or standalone, to support virus detection and assess the demand and effectiveness of infectious disease screening in community pharm... Read more


Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results

DUBLIN, Ireland, March 23, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2022 and fiscal year 2022. Summary Highlights Revenue: Total revenues for fiscal year 2022 and Q4, 2022 were $74.8m and $18.0m respectively. Excluding our Covid focused PCR Viral Transport Media (“VTM”)... Read more


CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association

CareDx to Host Symposium Featuring the Latest Developments in Pediatric Transplant Care BRISBANE, Calif. / Mar 23, 2023 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the International... Read more


Henry Schein to Host Pre-conference Program at the 2023 ADSO Annual Summit

Program to Feature a Panel Discussion with Company CEO Stanley Bergman and Jeannie Diefenderfer, CEO of the Higher Ambition Leadership Alliance MELVILLE, N.Y. / Mar 23, 2023 / Business Wire / In collaboration with the Association of Dental Support Organizations (ADSO), Henry Schein, Inc. (Nasdaq: HSIC) today announced that it will present a pre-conference program on Tuesday, March 28 from 2:30 – 5:30 pm at the 2023 ADSO Annual Summit. Open to all registered attendees... Read more


Nyxoah Announces a $15 Million Private Placement Financing

Mont-Saint-Guibert, Belgium – March 23, 2023, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced a €13.35 million private placement financing from the sale of 2,047,544 new ordinary shares at a price per share of €6.52 (approximately U.S. $7.10... Read more


MIMEDX Announces Chief Financial Officer Transition

MARIETTA, Ga., March 23, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that Peter M. Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities. The Company has initiated a search for its next Chief Financial Officer and Mr. Carlson will be assisting MIMEDX throughout this process to ensure a smooth transition. “In the three... Read more


Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

GARDEN CITY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid... Read more


Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through...

Widely Published Interventional Radiologist Has Earned Well-Regarded Reputation Working with Prestigious Medical Centers in the U.S. and Europe The addition of Professor O’Sullivan, the Clinical Director of Radiology for the Galway Clinic in Ireland, Expands the Company’s EU Presence. HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global interest from interventional radiologists due to the gap in new... Read more


ReShape Lifesciences Announces Formation of International Scientific Advisory Board

SAN CLEMENTE, Calif., March 23, 2023 (GLOBE NEWSWIRE) --  ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the formation of a Scientific Advisory Board (SAB). Members include internationally recognized experts and surgeons in the obesity and metabolic disease fields. The newly created SAB will provide management with strategic input and external scientific review of the company’s... Read more


Eargo Reports Fourth Quarter 2022 Financial Results

Recent Highlights: Net revenues of $12.9 million in the fourth quarter of 2022, compared to $10.1 million in the fourth quarter of 2021 and $7.9 million in the third quarter of 2022 Gross systems shipped of 8,863, compared to 7,767 in the fourth quarter of 2021 GAAP operating loss $23.9 million in the fourth quarter of 2022, compared to $45.2 million in the fourth quarter of 2021 and $26.0 million in the third quarter of 2022 Cash and cash equivalents of $101.2 million... Read more


Medtronic to boost AI innovation with new platform introduction

A strategic collaboration with Cosmo Pharmaceuticals  and NVIDIA delivers the GI Genius™ AI Access™ platform designed to accelerate AI innovation for healthcare. DUBLIN, March 22, 2023 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced Cosmo Pharmaceuticals and NVIDIA plan to integrate NVIDIA's AI technologies into the GI Genius™ intelligent endoscopy module — the first FDA-cleared, AI-assisted colonoscopy... Read more



Syneos Health and KX Partner to Pioneer Data-Driven Transformation in Biopharmaceutical Asset Development

MORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with KX, maker of kdb, the world’s fastest time series database and analytics engine. The partnership will deliver data-driven predictive analytics, Artificial Intelligence (AI) and Machine Learning (ML) capabilities to help customers address complex healthcare decisions via the... Read more


Quest Diagnostics Unveils Advanced Transplant Diagnostic Services Featuring Anywhere-Access in the United States

New capabilities include personalized patient access to Quest's national network of 2,100 patient service centers and 5,000 mobile and at-home phlebotomists, to support patient-compliant pre- and post-transplant testing and nationwide access, regardless of surgical center location SECAUCUS, N.J., March 22, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled a comprehensive suite of advanced... Read more


Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize patient selection for clinical trials. FT. MYERS, Fla. & NEW YORK / Mar 22, 2023 / Business Wire / Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics, Inc. (NASDAQ: NEO),... Read more


New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma

Real-world findings from >550 plasma samples highlight prognostic and predictive value of Signatera for adjuvant decision-making and immunotherapy monitoring AUSTIN, Texas / Mar 22, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to... Read more


Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

NOV03 Consistently Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction NOV03 PDUFA Action Date is June 28, 2023 VAUGHAN, Ontario & HEIDELBERG, Germany / Mar 22, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and... Read more


Nanox.AI Expands Footprint Through New Global Partnership with Ferrum Health

NEVE ILAN, Israel, March 22, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that that its deep-learning medical imaging analytics subsidiary, Nanox.AI, has entered into strategic partnership, with Ferrum Health, a leading player in the AI platform market. This partnership will broaden the reach of Nanox AI’s technology for medical imaging including Nanox.AI’s Bone... Read more


Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases

The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's expertise in drug discovery to address high unmet needs among rare disease patients  SAN FRANCISCO, March 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company, a healthcare investment firm, today announced a partnership to advance genetics-based drug discovery and development in rare... Read more


Trinity Biotech Welcomes TrinScreen HIV’s Inclusion In The New Kenyan HIV Testing Algorithm

DUBLIN, Ireland, March 22, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today welcomed the announcement by the Kenyan Ministry of Health of the adoption of a new HIV rapid testing algorithm. This new algorithm establishes Trinity Biotech’s TrinScreen HIV as the screening test (A1 = screen test under World Health Organisation... Read more


Inspira™ Technologies Announces First in Human of HYLA™ Blood Sensor in Clinical Study

First use of HYLA in a patient undergoing open-heart surgery at Sheba Medical Center in Israel RA'ANANA, Israel, March 22, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced today the first in human of a patient undergoing open-heart surgery in the HYLA research clinical study at Sheba Medical Center, Israel. The... Read more


Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device

Agreement extends existing partnership  Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area and will greatly strengthen Helius’s presence in the region  NEWTOWN, Pa., March 22, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, and HealthTech Connex Inc.... Read more


Applied DNA Sciences Submits Validation Package to New York State Department of Health for Approval of Pharmacogenomic (PGx) Assay

Expansion of Population-Scale Molecular Diagnostics Menu Positions ADCL Subsidiary for Long-Term Growth STONY BROOK, N.Y. / Mar 22, 2023 / Business Wire / Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a validation package to the New York State Department of Health (NYSDOH) in support of approval... Read more


Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction

SILVER SPRING, Md. and IRVINE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, and Sientra, Inc. (Nasdaq: SIEN) (“Sientra”), a medical aesthetics company uniquely focused on plastic surgery, today announced they have entered into an agreement to expand the distribution of Aziyo’s... Read more


CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)

PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced its scientific program for the 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM 2023) Congress being held this week in Brussels, Belgium.  Importantly, new data from some of the latest studies will... Read more


Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda

GOLETA, Calif. / Mar 22, 2023 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of Directors, effective April 1, 2023. The company also announced that Kristen Miranda, who has served as a director since March 2021, will retire as a member of the Board of Directors, effective March 31, 2023. “We are pleased to... Read more


Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Completed all 115 implants in the DREAM U.S. pivotal study Mont-Saint-Guibert, Belgium – March 22, 2023 09:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year 2022. Recent Financial and Operating... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB